Drug Profile
SC 109
Latest Information Update: 04 Jul 2000
Price :
$50
*
At a glance
- Originator Scotia Holdings [CEASED]
- Class Antiasthmatics
- Mechanism of Action Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Pulmonary fibrosis
Most Recent Events
- 04 Jul 2000 Discontinued-II for Asthma in United Kingdom (Unknown route)
- 04 Jul 2000 Discontinued-II for Pulmonary fibrosis in United Kingdom (Unknown route)
- 11 Jul 1997 Phase-II clinical trials for Asthma in United Kingdom (Unknown route)